Glue septal ablation: A promising alternative to alcohol septal ablation:
Sercan Okutucu,Kudret Aytemir,Ali Oto +2 more
- 01 Jan 2016
- Vol. 5, pp 2048004016636313-2048004016636313
TL;DR: Glue septal ablation (GSA) is a promising technique for the treatment of HOCM and seems to be superior to alcohol due to some intrinsic advantageous properties of glue such as immediate polymerization which prevents the leak into the left anterior descending coronary artery.
read more
Abstract: Hypertrophic cardiomyopathy (HCM) is defined as myocardial hypertrophy in the absence of another cardiac or systemic disease capable of producing the magnitude of present hypertrophy. In about 70% of patients with HCM, there is left ventricular outflow tract (LVOT) obstruction (LVOTO) and this is known as obstructive type of hypertrophic cardiomyopathy (HOCM). Cases refractory to medical treatment have had two options either surgical septal myectomy or alcohol septal ablation (ASA) to alleviate LVOT gradient. ASA may cause some life-threatening complications including conduction disturbances and complete heart block, hemodynamic compromise, ventricular arrhythmias, distant and massive myocardial necrosis. Glue septal ablation (GSA) is a promising technique for the treatment of HOCM. Glue seems to be superior to alcohol due to some intrinsic advantageous properties of glue such as immediate polymerization which prevents the leak into the left anterior descending coronary artery and it is particularly useful in patients with collaterals to the right coronary artery in whom alcohol ablation is contraindicated. In our experience, GSA is effective and also a safe technique without significant complications. GSA decreases LVOT gradient immediately after the procedure and this reduction persists during 12 months of follow-up. It improves New York Heart Association functional capacity and decrease interventricular septal wall thickness. Further studies are needed in order to assess the long-term efficacy and safety of this technique.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment
TL;DR: The aim of the current review is focused on two novel issues in a subgroup of obstructive HCM, associated with elevated level of signaling biomarkers: hypercoagulation, hemolysis, acquired von Willebrand 2A disease, and enhanced oxidative stress.
Conduction Disturbances and Arrhythmia Risk After Septal Reduction Therapy with Alternative Agents: A Pilot Study with EVOH-DMSO and Systematic Review.
Serkan Asil,Kudret Aytemir +1 more
TL;DR: In this paper , the authors compared and evaluated conduction system defects and arrhythmia risk after EVOH-DMSO septal ablation with other alternative agents and alcohol SEBP.
Non-surgical septal reduction therapy in hypertrophic cardiomyopathy
TL;DR: The mitral valve is proposed to be abnormal as part of the HCM phenotype, with a variety of changes such as longer leaflets, abnormal papillary muscle architecture and anterior displacement of the apparatus.
12
Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Transcoronary and Endocardial Approach.
TL;DR: This review aimed to present nonsurgical septal reduction approaches in patients with hypertrophic obstructive cardiomyopathy.
9
Conduction of excitation waves and reentry drift on cardiac tissue with simulated photocontrol-varied excitability.
Aygul Nizamieva,I. Y. Kalita,M. M. Slotvitsky,A. Berezhnoy,N. S. Shubina,S. R. Frolova,V. A. Tsvelaya,Konstantin Agladze +7 more
TL;DR: In this article , the authors investigated the effect of a simulated excitability gradient in cardiac cell culture on the behavior and termination of reentry waves, and found that the drift direction depended on the observation time due to the meandering of the spiral wave.
8
References
Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases
Perry M. Elliott,Bert Andersson,Eloisa Arbustini,Zofia T. Bilińska,Franco Cecchi,Philippe Charron,Olivier Dubourg,Uwe Kühl,Bernhard Maisch,William J. McKenna,Lorenzo Monserrat,Sabine Pankuweit,Claudio Rapezzi,Petar M. Seferović,Luigi Tavazzi,Andre Keren +15 more
TL;DR: This document, The European Society of Cardiology Working Group on Myocardial and Pericardial Diseases presents an update of the existing classification scheme, to help clinicians look beyond generic diagnostic labels in order to reach more specific diagnoses.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Barry J. Maron,William J. McKenna,Gordon K. Danielson,Lukas Kappenberger,Horst J. Kuhn,Christine E. Seidman,Pravin M. Shah,William H. Spencer,Paolo Spirito,Folkert J. Ten Cate,E. Douglas Wigle,Robert A. Vogel,Jonathan Abrams,Eric R. Bates,Bruce R. Brodie,Peter G. Danias,Gabriel Gregoratos,Mark A. Hlatky,Judith S. Hochman,Sanjiv Kaul,Robert C. Lichtenberg,Jonathan R. Lindner,Robert A. O'Rourke,Gerald M. Pohost,Richard S. Schofield,Cynthia M. Tracy,William L. Winters,Werner Klein,Silvia G. Priori,Angeles Alonso-Garcia,Carina Blomström-Lundqvist,Guy De Backer,Jaap W. Deckers,Markus Flather,Jaromír Hradec,Ali Oto,Alexander Parkhomenko,Sigmund Silber,Adam Torbicki +38 more
TL;DR: In this paper, the authors present a general approach for the natural history and clinical course of clinical diagnostics in the context of vascular flow outflow and genetic and molecular diagnostics.
1.6K
Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy
TL;DR: A novel catheter-based technique that may replace surgical myocardial reduction in some patients with hypertrophic obstructive cardiomyopathy, which aims at selective destruction of the hypertrophied part of the left side of the intraventricular septum.
767
Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up
TL;DR: Nonsurgical septal reduction therapy is an effective therapy for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence of the favorable outcome up to one year after the procedure.
157
Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up
Eric Durand,Elie Mousseaux,Pierre Coste,Rémy Pillière,Olivier Dubourg,Ludovic Trinquart,Gilles Chatellier,Albert Hagège,Michel Desnos,Antoine Lafont +9 more
TL;DR: The results of this pilot non-randomized study suggest that non-surgical septal myocardial reduction by coil embolization in HOCM is feasible and does not induce CHB.
64